Literature DB >> 6176108

Angiotensin-converting enzyme inhibition in congestive heart failure: the concept.

J N Cohn, T B Levine.   

Abstract

Plasma renin activity frequently is increased in patients with congestive heart failure. This increase in inversely related to serum sodium concentration, but is not correlated with hemodynamic measurements. Nonetheless, inhibition of converting enzyme activity by administration of teprotide or captopril results in a decrease in systemic vascular resistance that is directly related to the control plasma renin activity. These data suggest that angiotensin II contributes to the systemic vasoconstriction of heart failure and that chronic inhibition of the renin-angiotensin system may have a salutary effect on left ventricular performance in patients with heart failure.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6176108     DOI： 10.1016/0002-9149(82)90364-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

1.  Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure.

Authors:  T R Shaw; F M Duncan; B C Williams; E Crichton; S A Thomson; J R Davis; M Rademaker; C R Edwards
Journal:  Br Heart J       Date:  1985-08

2.  Non-invasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats.

Authors:  Ahmad I M Al-Shafei; R G Wise; G A Gresham; G Bronns; T A Carpenter; L D Hall; Christopher L-H Huang
Journal:  J Physiol       Date:  2002-01-15       Impact factor: 5.182

3.  Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A.

Authors:  G Waeber; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.

Authors:  J P Bussien; J Nussberger; M Porchet; B Waeber; H R Brunner; M Perisic; M J Tansey; M Bomm; P Hajdu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

5.  Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.

Authors:  M D Schaller; J Nussberger; B Waeber; J P Bussien; G A Turini; H Brunner; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure.

Authors:  J A Romankiewicz; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.